Macular Degeneration: BioTime Announces

BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD ALAMEDA, Calif.–(Business Wire)–BioTime, Inc., a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced new data from the Phase I/IIa clinical trial… read more →